Successful Data Partner Calls in AML and MM
Over the months of October and November, the HARMONY Alliance Foundation launched two calls for data partners focusing on acute myeloid leukemia (AML) and multiple myeloma (MM). These initiatives were designed to respond to a clear and pressing need: to refresh and expand the data available on the HARMONY Platform, ensuring it accurately reflects the rapidly evolving treatment landscape for patients living with these diseases.
Just two months after their launch, the response from the hematology community has been truly impressive.
In a matter of six weeks, we received expressions of interest from 30 centers across Europe and beyond, all willing to contribute data from their hospitals, laboratories, and registries, and join this large-scale collaborative effort. According to the information provided through the dedicated submission forms, these contributions have the potential to bring together:
- More than 4,200 cases of AML, including patients treated with standard-of-care chemotherapies combined with targeted therapies
- Over 4,800 cases of MM patients treated after first relapse, significantly strengthening real-world evidence in this critical disease setting.
This strong engagement highlights the shared commitment of the hematology community to advance data-driven research, support regulatory and clinical decision-making, and ultimately improve outcomes for patients with AML and MM.
You can still join the effort
If you missed the original calls, it is not too late to contribute. We continue to welcome expressions of interest from data holders who wish to take part in this collaborative initiative.
You can join the effort by filling out the forms below:
- AML call for data partners – Click here to send your Expression of Interest
- MM call for data partners – Click here to send your Expression of Interest
Together, we can continue to enrich the HARMONY Platform and accelerate impactful, evidence-based research in hematological malignancies.